Gelhorn Heather L, Boye Kristina S, Shalhoub Huda, Matza Louis S, Jordan Jessica B, Alhammad Ali, Anand Savita B, Ekhzaimy Aishah A, Strizek Alena
Evidera, Bethesda, MD, USA.
Eli Lilly and Company, Indianapolis, IN, USA.
Patient Prefer Adherence. 2020 Nov 10;14:2231-2242. doi: 10.2147/PPA.S265126. eCollection 2020.
The Kingdom of Saudi Arabia (KSA) has the second highest prevalence of type 2 diabetes mellitus (T2DM) in the Middle East. There is a paucity of research on the experiences and treatment preferences of patients with T2DM in KSA. This study explored Saudi patients' health-related quality of life, eating habits, experiences during Ramadan, and preference between two glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment devices.
A cross-sectional, observational study was conducted in three cities in KSA. Participants completed sociodemographic and clinical forms, EQ-5D-5L, Impact of Weight on Self-Perceptions, and a diabetes treatment survey. Participants also viewed instructional videos on GLP-1 RA injection devices and indicated their device preference.
Of the 310 participants, 53% were male. The mean age was 43 years (range: 30.0-75.0), duration since diabetes diagnosis was 6.3 years (range: 0.2-27.1), the most commonly reported last HbA1c level was between ≥7.1% and 8% (45%). The mean EQ-5D-5L index score was 0.90, with some participants reporting problems with pain/discomfort (34.5%) and usual activities (33.2%). Patients reported a low-to-moderate impact of weight on self-perception. In preparation for Ramadan, participants sought physician advice on diabetes management (37%) and/or increased checks of their blood glucose (37%). After watching the videos, 89% (n=277) of participants indicated a device preference, with significantly more preferring the dulaglutide device (n=186, 67%) over the semaglutide device (n=91, 33%) (p<0.0001).
This study indicates that T2DM has a significant social, emotional, and behavioral impact on the lives of patients in KSA.
沙特阿拉伯王国（KSA）的2型糖尿病（T2DM）患病率在中东地区位居第二。关于沙特阿拉伯T2DM患者的经历和治疗偏好的研究较少。本研究探讨了沙特患者的健康相关生活质量、饮食习惯、斋月期间的经历以及两种胰高血糖素样肽-1受体激动剂（GLP-1 RA）治疗装置之间的偏好。
在沙特阿拉伯的三个城市进行了一项横断面观察性研究。参与者完成了社会人口统计学和临床表格、EQ-5D-5L量表、体重对自我认知的影响量表以及一项糖尿病治疗调查。参与者还观看了关于GLP-1 RA注射装置的教学视频，并表明了他们对装置的偏好。
在310名参与者中，53%为男性。平均年龄为43岁（范围：30.0 - 75.0岁），自糖尿病诊断以来的病程为6.3年（范围：0.2 - 27.1年），最常报告的末次糖化血红蛋白（HbA1c）水平在≥7.1%至8%之间（45%）。EQ-5D-5L指数的平均得分为0.90，一些参与者报告了疼痛/不适（34.5%）和日常活动方面（33.2%）的问题。患者报告体重对自我认知的影响为低到中度。在为斋月做准备时，参与者寻求医生关于糖尿病管理的建议（37%）和/或增加血糖检查（37%）。观看视频后，89%（n = 277）的参与者表明了对装置的偏好，明显更多的人更喜欢度拉糖肽装置（n = 186，67%）而非司美格鲁肽装置（n = 91，33%）（p < 0.0001）。
本研究表明，T2DM对沙特阿拉伯患者的生活有重大的社会、情感和行为影响。
